WinstonWınston
Clearday logo

Clearday

CLRD
Medical - Care Facilities · Healthcare
Price
$0.00
+0.00 (+0.00%)
Market Cap
$65,435
Winston Score
Winston looking sleepy
No score yet — Winston is napping.
We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+1784.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 987K (2018) → 18.6M (2022)

Clearday, Inc. is a small healthcare company focused on providing care services for older adults, including memory care and adult day programs. Its main customers are seniors and their families who need help with daily living, especially those dealing with conditions like Alzheimer's or dementia. The company operates in the long-term care and senior services industry, which is growing as the U.S. population ages.

Clearday earns revenue by charging fees for its care programs and facilities, rather than through subscriptions or software. It is a very small company with a market cap near zero, meaning it has limited financial resources compared to larger care facility operators. The company has been losing money, as shown by its negative return on invested capital, and its main risk is securing enough funding to keep operating and expanding its services while competing against much larger, better-capitalized healthcare providers.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-72.8% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-233.3% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

32.0%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~1 months

$99,810 cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Cash watch

Clearday has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
12.3%
Thin — 12.3% gross margin
Operating Margin
-214.4%
Losing money on operations — -214.4%
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-39.1%
Shrinking sales (-39.1% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
-68.2%
Burning cash (-68.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial